Nephrology

Your Article Summary

See Latest Articles

Clinical implications of hypoxia inducible factor in renal cell carcinoma
Urologic Oncology: Seminars and Original Investigations, 06/29/09

Smaldone MC et al. - In a review of the clinical implications of hypoxia inducible factor (HIF) in renal cell carcinoma (RCC), this report provides a directed review of recent discoveries defining the role of HIF in renal tumorigenesis and their relevance to clinical advances in targeted therapy for advanced RCC.

• Management of RCC has made considerable strides in the past decade, due in large part to identification of the von Hippel Lindau (VHL) tumor suppressor as a negative regulator of HIF-α protein expression.

• Stabilization of HIF-α appears to be critical for renal tumorigenesis, and is observed even in VHL-independent RCC.
• An understanding of the pathways that regulate expression and activation of the different HIF-α isoforms is key to delineating the mechanism of renal transformation and for development of novel therapeutics.
• A number of agents targeting HIF-α or its transcriptionally-regulated genes have shown promise in treatment of RCC.
• More effective treatment strategies are still needed.

Today in Hematology/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09

A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia
Clinical Journal of the American Society of Nephrology, 11/05/09

Incidence of brain metastases in renal cell carcinoma treated with sorafenib
Annals of Oncology, 10/29/09

See All of Hematology/Oncology